whats the deal, page-4

Who knows, but with the recent settlement with GSK there has got to be something else happening behind the scenes. Perhaps GSK are interested in marketing LANI? Why not, it fits in with their other vaccine programs just nicely.

I have severe doubts as to the Biota negotiating ability. I'll be looking for a 50% royalty for LANI (which will be split 50 50 with Sankyo). They should wait till Phase III completing over our coming summer i.e. Northern winter.

BTA is cheap but the market obviously is treading carefully. The last royalty figure was rock bottom! Without the royalties and prospect of large settlement Biota is nothing more than a cash burning biotech with prospective pipeline. A gamble in other words.